Recent Updates
Recently added Catalysts
TSHA Positive Sentiment Score: 80/100

Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting

Thursday, April 27, 2023 2 min read
Key Takeaway: Taysha Gene Therapies announced that it will present new preclinical data for its TSHA-102 program at the American Society of Gene and Cell Therapy's 26th Annual Meeting. The presentation will focus on a study showing improvements in survival, weight, and behavior in a mouse model of Rett syndrome. TSHA-102 is an AAV9 gene transfer therapy currently under evaluation for this rare neurodevelopmental disorder. This presentation may enhance Taysha's visibility within the gene therapy field.

Market Sentiment Analysis

POSITIVE FACTORS

  • TSHA-102 shows promise in improving survival and behavior in a Rett syndrome model.
  • Presentation at ASGCT could raise awareness and interest in Taysha's pipeline.
  • The acceptance of their abstract indicates recognition of their research in the scientific community.

Full Press Release Details

DALLAS, April 27, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that an abstract related to its TSHA-102 program in Rett syndrome was accepted for presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, taking place in Los Angeles, CA from May 16-20, 2023. The abstract includes new preclinical data from a Taysha-sponsored study for TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome, a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene.
Details for the presentation are as follows:
Abstract Title: A Human-Ready Regulated AAV9/miniMECP2-miRARE Gene Therapy (TSHA-102) Improves Survival, Weight, and Behavior After Intracerebroventricular (ICV) Dosing in the Neonatal Knockout Rett (RTT) Mouse Model
Presenter: Sarah Sinnett, Ph.D., University of Texas Southwestern Medical Center, Co-Inventor of miRARE technology
Poster Session Date/Time: Friday, May 19 at 12-2 PM PT
Poster Session: Friday Poster Session
Additional details can be found at the ASGCT 26th Annual Meeting website.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
Director, Head of Corporate Communications
Taysha Gene Therapies
hcollins@tayshagtx.com
Canale Communications
carolyn.hawley@canalecomm.com

Frequently Asked Questions

What is Taysha Gene Therapies focused on?

Taysha Gene Therapies develops AAV-based gene therapies for CNS monogenic diseases.

What program related to Rett syndrome was presented?

The TSHA-102 program's abstract, showcasing preclinical data, was accepted for presentation.

When is the ASGCT Annual Meeting held?

The ASGCT Annual Meeting takes place from May 16-20, 2023, in Los Angeles, CA.

Who presented the TSHA-102 program abstract?

Dr. Sarah Sinnett from UT Southwestern Medical Center presented the abstract.

What does TSHA-102 aim to improve?

TSHA-102 aims to improve survival, weight, and behavior in Rett syndrome models.

Tags: TSHA Viatris Investor Conferences Healthcare Taysha Gene Therapies TSHA-102 Rett syndrome AAV9 therapy ASGCT
Last updated: Apr 27, 2023